# Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood

> **NCT02533895** · PHASE1 · COMPLETED · sponsor: **Activartis Biotech** · enrollment: 67 (actual)

## Conditions studied

- Childhood Solid Tumor

## Interventions

- **BIOLOGICAL:** AV0113 DC-CIT
- **OTHER:** Data evaluation

## Key facts

- **NCT ID:** NCT02533895
- **Lead sponsor:** Activartis Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-10
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2015-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533895, "Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02533895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*